Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3370 | Rilpivirine extended release suspension for injection (long-acting) Wiki | 1.00 |
| drug823 | Cabotegravir Tablets Wiki | 0.71 |
| drug3369 | Rilpivirine Tablets Wiki | 0.71 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a phase 1, open label study in healthy participants to assess the pharmacokinetics of cabotegravir and rilpivirine in plasma following the administration of a single 600 milligram (mg) and a 900 mg intramuscular (IM) injection respectively, to separate vastus lateralis muscles on each leg. Cabotegravir is an integrase inhibitor being developed in combination with rilpivirine, a non-nucleoside reverse transcriptase inhibitor, for the treatment of human immunodeficiency virus (HIV). The objective is to evaluate pharmacokinetics, tolerability, and safety of cabotegravir long acting plus rilpivirine long acting administered concomitantly as two separate IM injections in the vastus lateralis muscle of adult healthy participants. The screening phase will be of 30 days, oral lead-in (OLI) phase of 28 days, there will be washout period of 10-14 days, followed by an injection phase and follow-up period will be up to 52-weeks. Approximately 15 adult healthy participants will be enrolled.
Description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cabotegravir.
Measure: Maximum observed concentration (Cmax) for cabotegravir (injection phase) Time: Day 1 (Pre-dose, 1 hour, 2 hours) and one post-dose sample on Day 2, Day 4, Day 5, Day 7, Day 10, Day 15, Day 17, Day 22 and Day 28Description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cabotegravir.
Measure: Time of Cmax (Tmax) for cabotegravir (injection phase) Time: Day 1 (Pre-dose, 1 hour, 2 hours) and one post-dose sample on Day 2, Day 4, Day 5, Day 7, Day 10, Day 15, Day 17, Day 22 and Day 28Description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cabotegravir.
Measure: Area under the plasma concentration-time curve from time zero to time (AUC[0-t]) for cabotegravir (injection+follow-up phase) Time: Day 1 (Pre-dose, 1 hour, 2 hours) and one post-dose sample on Day 2, Day 4, Day 5, Day 7, Day 10, Day 15, Day 17, Day 22, Day 28, Week 8, Week 12, Week 24, Week 36 and Week 52Description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cabotegravir.
Measure: Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC[0-infinity]) for cabotegravir (injection+follow-up phase) Time: Day 1 (Pre-dose, 1 hour, 2 hours) and one post-dose sample on Day 2, Day 4, Day 5, Day 7, Day 10, Day 15, Day 17, Day 22, Day 28, Week 8, Week 12, Week 24, Week 36 and Week 52Description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cabotegravir.
Measure: Apparent terminal phase half-life (t1/2) for cabotegravir (follow-up phase) Time: One post-dose sample at Week 8, Week 12, Week 24, Week 36, and Week 52Description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of cabotegravir.
Measure: Absorption rate constant for cabotegravir (follow-up phase) Time: One post-dose sample at Week 8, Week 12, Week 24, Week 36, and Week 52Description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of rilpivirine.
Measure: Cmax for rilpivirine (injection phase) Time: Day 1 (Pre-dose, 1 hour, 2 hours) and one post-dose sample on Day 2, Day 4, Day 5, Day 7, Day 10, Day 15, Day 17, Day 22 and Day 28Description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of rilpivirine.
Measure: Tmax for rilpivirine (injection phase) Time: Day 1 (Pre-dose, 1 hour, 2 hours) and one post-dose sample on Day 2, Day 4, Day 5, Day 7, Day 10, Day 15, Day 17, Day 22 and Day 28Description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of rilpivirine.
Measure: AUC(0-t) for rilpivirine (injection+follow-up phase) Time: Day 1 (Pre-dose, 1 hour, 2 hours) and one post-dose sample on Day 2, Day 4, Day 5, Day 7, Day 10, Day 15, Day 17, Day 22, Day 28, Week 8, Week 12, Week 24, Week 36 and Week 52Description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of rilpivirine.
Measure: AUC(0-infinity) for rilpivirine (injection+follow-up phase) Time: Day 1 (Pre-dose, 1 hour, 2 hours) and one post-dose sample on Day 2, Day 4, Day 5, Day 7, Day 10, Day 15, Day 17, Day 22, Day 28, Week 8, Week 12, Week 24, Week 36 and Week 52Description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of rilpivirine.
Measure: t1/2 for rilpivirine (follow-up phase) Time: One post-dose sample at Week 8, Week 12, Week 24, Week 36, and Week 52Description: Blood samples will be collected at indicated time points for pharmacokinetic analysis of rilpivirine.
Measure: Absorption rate constant for rilpivirine (follow-up phase) Time: One post-dose sample at Week 8, Week 12, Week 24, Week 36, and Week 52Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports